Hydroxychloroquine/Teva (hydroxychloroquine sulfate)
We support you to access approved medicine that is not approved or available in your country of residence. Make an enquiry below to learn more.
Our mission is to safeguard the health of our patients by supporting them to access safe and life-improving medicines.
For that reason TheSocialMedwork will not provide access to Hydroxycholoroquine to treat patients with COVID-19 following the recent WHO decision to suspend its Solidarity Trial of Hydroxycholoroquine until the safety data is reviewed by its Data Safety Monitoring Board.
Please only submit an enquiry for this medicine if you need it for its prescribed and approved purpose.
Hydroxychloroquine Teva (hydroxychloroquine sulfate) is a generic drug of Plaquenil (hydroxychloroquine sulfate) and is a medicine for treating uncomplicated malaria, chronic discoid lupus erythematosus, systemic lupus erythematosus, and acute and chronic rheumatoid arthritis in adults.
The packaging size and strength below may vary due to product availability. Please contact us to verify price and availability.
Manufacturer
Teva Pharmaceuticals
Usage
Oral
Medicine approved by
-
European Medical Agency (EMA)
-
Food and Drug Administration (FDA)
-
Health Canada
-
Therapeutic Goods Administration (TGA)
-
Medsafe (NZ)
Patients helped
- Over 1.2 million patients reached
- Over 11,000 patients helped
- 13,000 medicines supplied
- 100% success delivering to people in 85 countries
Safe and Secure
We are registered with the Dutch Ministry of Health in The Hague, as an intermediary, registration number: 6730 BEM and as a wholesale distributor, registration number: 16258 G.
Package
Our patients share their stories
Read more
Note that Hydroxychloroquine Teva (hydroxychloroquine sulfate) is a generic drug of Plaquenil (hydroxychloroquine sulfate)1 and is indicated for the treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium ovale, and plasmodium vivax. It is also indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. The precise mechanism by which hydroxychloroquine exhibits activity against plasmodium is not known. Hydroxychloroquine, like chloroquine, is a weak base and may exert its effect by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA.2
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
Contraindications
Use of hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. Use with caution in patients with gastrointestinal, neurological, or blood disorders, and in those with a sensitivity to quinine.2
Side effects
Some serious and common side effects listed in the prescribing information include2:
-
bone marrow failure
-
cardiomyopathy
-
vertigo
-
irreversible retinopathy
-
nausea
-
fatigue
Please refer to the summary of product characteristics below and in the resource section for comprehensive information about the safety and effectiveness of Hydroxychloroquine Teva (hydroxychloroquine sulfate) for the approved indication1,2,3,4,5,6.
References
1. Full prescribing information [FDA]: Plaquenil (hydroxychloroquine sulfate) [PDF], Concordia, June 2018.
2. Full prescribing information [FDA]: Hydroxychloroquine Teva (hydroxychloroquine sulfate) [PDF], Teva, Nov 2017.
3. Public assessment report [CBG, NL]: Hydroxychloroquine sulfate [PDF], College Ter Beoordeling van Geneesmiddelen, Jan 2019.
4. Product information [TGA]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, December 2019.
5. Product monograph [Health Canada]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, August 2019.
6. Product detail [Medsafe]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, December 2018.
Four steps to access the medicines you need
How and where to buy Hydroxychloroquine/Teva: You can order Hydroxychloroquine/Teva from TheSocialMedwork if the drug has not been approved or is not available in your country.
-
Step 1
You send a request for your medicine online
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.
-
Step 2
We verify your prescription and medical details
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.
-
Step 3
We source your medicine
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
-
Step 4
We deliver your medicine
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. We will work hard to keep you informed at every step along the way and get your medicine to you quickly and safely. To date we have successfully delivered packages to over 75 countries around the world.
FDA agrees to phase 3 clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease (ongoing)
The FDA has agreed to a phase 3, randomized, double-blind, placebo-controlled study with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. Patients are randomized into three arms: treatment with hydroxychloroquine; hydroxychloroquine in combination with azithromycin, which is an antibiotic therapy; and placebo. Patients in all treatment groups are receiving standard of care for COVID-19.9
SOLIDARITY trial (ongoing)
The World Health Organization (WHO) is focusing on what it says are the four most promising therapies for COVID-19: an experimental antiviral compound called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of two HIV drugs, lopinavir and ritonavir; and that same combination plus interferon-beta, an immune system messenger that can help cripple viruses. This was initiated by the WHO on March 20, 2020. Enrolling subjects in SOLIDARITY is easy. When a person with a confirmed case of COVID-19 is deemed eligible, the physician can enter the patient’s data into a WHO website, including any underlying condition that could change the course of the disease, such as diabetes or HIV infection. The participant has to sign an informed consent form that is scanned and sent to WHO electronically. After the physician states which drugs are available at his or her hospital, the website will randomize the patient to one of the drugs available or to the local standard care for COVID-19. Physicians will record the the duration of the hospital stay or death, and whether the patient required oxygen or ventilation.4
Discovery (add-on) trial (ongoing)
On March 22, 2020, the French biomedical research agency INSERM announced they would conduct an add-on study to SOLIDARITY. They will follow WHO’s example and will include 3200 patients from at least seven countries, including 800 from France. This trial will test the same drugs, with the exception of chloroquine.4
Update on trial suspension:
A Hydroxycholoroquine paper published by The Lancet on the 22 of May 2020 has highlighted the inconclusive evidence of this medicine in combating COVID-19.10
On the 25th of May 2020, the World Health Organisation announced that it will suspend its Solidarity Trial of Hydroxycholoroquine until the safety data is reviewed by its Data Safety Monitoring Board. 11
References
1. Full prescribing information [FDA]: Plaquenil (hydroxychloroquine sulfate) [PDF], Concordia, June 2018.
2. Full prescribing information [FDA]: Hydroxychloroquine Teva (hydroxychloroquine sulfate) [PDF], Teva, Nov 2017.
3. Information for Clinicians on Therapeutic Options for COVID-19 Patients. Accessed March 2020.
4. WHO launches global megatrial of the four most promising coronavirus treatments. Accessed March 2020.
5. Public assessment report [CBG, NL]: Hydroxychloroquine sulfate [PDF], College Ter Beoordeling van Geneesmiddelen, Jan 2019.
6. Product information [TGA]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, December 2019.
7. Product monograph [Health Canada]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, August 2019.
8. Product detail [Medsafe]: Plaquenil (hydroxychloroquine sulfate) [PDF], Sanofi-Aventis, December 2018.
9. Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients. Accessed April 2020.
11. WHO Director-General's opening remarks at the media briefing on COVID-19 - 25 May 2020
Room temperature shipping
For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order.
Our standard delivery time varies from 5 to 10 working days.
The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.
You can also pick up your medicine from our partner pharmacy in Amsterdam or our partner pharmacy in Luxembourg after the order has been paid for.
Patient reviews
“I want to recommend everyone to work with this organization. They are reliable, honest, punctual and do everything to meet your needs…”
“Dr. Aysen Simsek and her team offered assistance during a very difficult time. I truly appreciate their quick, efficient and professional attitude, as well as their patience and superb customer service…”
“I highly recommend TheSocialMedwork. They welcomed me with open arms when I went to their office in Amsterdam. I was in a very difficult situation with a tight schedule, and their amazing team members…”
We are highly rated by our patients
About us
We are TheSocialMedwork, a registered medical intermediary that helps you access elsewhere approved medicines, no matter where you live. To date, we have assisted patients in over 80 countries to access thousands of life-improving medicines.
Learn moreAbout us
Disclaimer
Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.
